The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

Binod Dhakal, MD, MS, discusses how the efficacy results observed with ciltacabtagene autoleucel in the CARTITUDE-4 trial compare with other therapies that are used for the treatment of ...

They were driven by new pharmaceutical launches (up 67.1% to €727 million), including Altuviiio, used to treat haemophilia, Tzield - for type 1 diabetes -, Sarclisa (multiple myeloma) and Rezurock, ...

Also make sure to check our part 1 of our exclusive interview with her regarding the recent FDA approval of isatuximab (Sarclisa; Sanofi-Aventis) plus bortezomib (Velcade; Takeda), lenalidomide ...

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...

It also vowed to keep Opella's headquarters in France, the same source added. Read also: USFDA nod to Sanofi Sarclisa in combo with bortezomib, lenalidomide, dexamethasone for newly diagnosed multiple ...

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

NEWS ANALYSIS: Norwegian Prime Minister Jonas Gahr Støre was quick to congratulate Donald Trump on Wednesday, even before the final vote in the US presidential election was tallied. Støre stressed ...

The FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, building on a first approval last year. This label extension ...